The company has applied to list its common stock on the
While G1 has no approved cancer drugs on the market, the company said it has two promising candidates in its pipeline. It is developing an intravenous drug, called trilaciclib, to protect the bone marrow and immune systems of cancer patients receiving chemotherapy as well as an oral drug to stifle the cell division of breast cancer tumors.
Trilaciclib is currently in Phase 2 trials and G1T38 is in Phase 1 trials. The capital from the IPO will be used to fund the development of those two clinical-stage candidates as well as earlier stage drugs.
The company has not revealed how many shares it plans to offer to the public or the price range of its shares — so the
G1 was founded in 2008 as G0 and renamed in 2012. Last year, the company raised
The company has 31 employees, according to its filing. Trilaciclib is not expected to be on the market until 2019 at the earliest, CEO
The company has accumulated a deficit of
G1 listed the financial firms J.P.
This will be the first IPO in the
(c)2017 The Herald-Sun (Durham, N.C.)
Visit The Herald-Sun (Durham, N.C.) at www.heraldsun.com
Distributed by Tribune Content Agency, LLC.